| __timestamp | BioMarin Pharmaceutical Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 44426000 |
| Thursday, January 1, 2015 | 152008000 | 46398000 |
| Friday, January 1, 2016 | 209620000 | 59897000 |
| Sunday, January 1, 2017 | 241786000 | 90296000 |
| Monday, January 1, 2018 | 315264000 | 89135000 |
| Tuesday, January 1, 2019 | 359466000 | 86125000 |
| Wednesday, January 1, 2020 | 524272000 | 96951000 |
| Friday, January 1, 2021 | 470515000 | 159938000 |
| Saturday, January 1, 2022 | 483669000 | 240813000 |
| Sunday, January 1, 2023 | 577065000 | 330123000 |
| Monday, January 1, 2024 | 580235000 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for BioMarin Pharmaceutical Inc. and Cytokinetics, Incorporated from 2014 to 2023. Over this period, BioMarin's cost of revenue surged by approximately 345%, reflecting its expanding operations and increased production capabilities. In contrast, Cytokinetics experienced a staggering 643% increase, indicating significant growth and investment in its pipeline. Notably, 2023 marked a pivotal year, with BioMarin reaching its peak cost of revenue, while Cytokinetics continued its upward trajectory. These trends underscore the competitive landscape and strategic investments in the biotech sector. As the industry evolves, monitoring these financial metrics provides valuable insights into company performance and market positioning.
Eli Lilly and Company vs Cytokinetics, Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Sanofi vs Cytokinetics, Incorporated
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: Biogen Inc. and Cytokinetics, Incorporated
Cost of Revenue Trends: BeiGene, Ltd. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.
BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: BioMarin Pharmaceutical Inc. vs Wave Life Sciences Ltd.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Galapagos NV
Cost of Revenue: Key Insights for Exelixis, Inc. and Cytokinetics, Incorporated
Cost of Revenue: Key Insights for Cytokinetics, Incorporated and Alkermes plc
Cost of Revenue Comparison: Cytokinetics, Incorporated vs Bausch Health Companies Inc.